Cargando…

DIPG-03. IDENTIFICATION OF NEW THERAPEUTIC TARGETS BY ARRAYED CRISPRA-BASED APPROACH TO MAP RADIORESISTANCE IN DMG

Pediatric Diffuse Midline Glioma (DMG) is amongst the most aggressive childhood brain tumors. The dismal prognosis is less than a year for children diagnosed. Radiotherapy (RT) remains the only standard treatment that provides only transient relief of clinical symptoms of DMG patients. Poor survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez, Solène, Laternser, Sandra, Sellitto, Stefano, Neupane, Sandesh, Petrovic, Antonela, Ciani, Ludovica, Kritzer, Bettina, Hasler, Kerstin, Bamert, David, Nazarian, Javad, Aguzzi, Adriano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliomas - DPIG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259895/ http://dx.doi.org/10.1093/neuonc/noad073.050

Ejemplares similares

DIPG-23. THE ROLE OF FOXO3 IN DMG RESISTANCE AND RESPONSE TO THERAPIES TARGETING DMG METABOLISM
por: Petrovic, Antonela, et al.
Publicado: (2023)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
por: Laspidea, Virginia, et al.
Publicado: (2023)

DIPG-07. ROBUST CGAS-STING PATHWAY MEDIATED-INDUCTION OF ANTITUMOR ADAPTIVE IMMUNE RESPONSE: A POTENTIAL FOR DMG IMMUNOTHERAPY
por: Umaru, Banlanjo, et al.
Publicado: (2023)

DIPG-47. DISCOVERING A MOLECULAR BASIS FOR VULNERABILITY OF H3K27M-DMG TO HISTONE DEACETYLASE INHIBITORS
por: Paine, Danyelle, et al.
Publicado: (2023)

DIPG-32. PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Balakrishnan, Ilango, et al.
Publicado: (2023)

DIPG-29. A CONNECT CONSORTIUM PRECLINICAL STUDY IDENTIFIES MEK INHIBITION AND RADIATION AS POTENTIAL COMBINATION PARTNERS FOR THE ALK2 INHIBITOR TP-0184 IN ACVR1-MUTANT DMG
por: Rogers, Rebecca, et al.
Publicado: (2023)

DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
por: Auffret, Lucie, et al.
Publicado: (2023)

DIPG-26. CLINICAL AND GENOMIC ANALYSIS OF H3K27M-DMG LONG-TERM SURVIVORS REVEALS ENRICHMENT IN MAPK PATHWAY ALTERATIONS
por: Roberts, Holly, et al.
Publicado: (2023)

DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS
por: Laternser, Sandra, et al.
Publicado: (2023)

DIPG-48. DIPG THROUGH THE LOOKING GLASS
por: Senga, Sasi S
Publicado: (2023)

DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
por: Hashizume, Rintaro, et al.
Publicado: (2023)

DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
por: Mishra, Deepak, et al.
Publicado: (2023)

DIPG-27. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) CHALLENGE: FROM GENE EXPRESSION PROFILE TO DRUG
por: Scilimati, Antonio, et al.
Publicado: (2023)

DIPG-42. MAPPING THE DNA METHYLATION LANDSCAPE OF DIPG REVEALS NOTABLE METHYLOME VARIABILITY RESPONSIVE TO PHARMACOLOGIC MODULATION
por: Tetens, Ashley, et al.
Publicado: (2023)

DIPG-14. PROTEOGENOMICS PROFILING REVEALS ENRICHED NON-HISTONE PROTEIN METHYLTRANSFERASES AS NEW THERAPEUTIC TARGETS IN DIPG
por: Anguraj Vadivel, Arun Kumaran, et al.
Publicado: (2023)

DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS
por: Ibanez, Jorge, et al.
Publicado: (2023)

DIPG-44. DIFFUSE MIDLINE GLIOMA WITH EXTRACRANIAL METASTASIS
por: Larsen, Alexandra Giantini, et al.
Publicado: (2023)

DIPG-52. EXTRAPONTINE PROGRESSION WITH STABLE PONTINE DISEASE POST-RADIOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ON A CONNECT TRIAL: IMPLICATIONS FOR RADIATION TREATMENT VOLUMES
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-01. LIN28B EXPRESSION IN DIFFUSE MIDLINE GLIOMA
por: Knowles, Truman, et al.
Publicado: (2023)

DIPG-50. INSIGHTS INTO TUMORIGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMA-ONCOHISTONE AND SIGNALING
por: Sun, Ye, et al.
Publicado: (2023)

DIPG-39. SIGNALING NETWORKS IN PEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMAS
por: Herbst, Sophie A, et al.
Publicado: (2023)

DIPG-35. IDENTIFYING DRIVER-SPECIFIC VULNERABILITIES IN PAEDIATRIC HIGH GRADE GLIOMA SUBTYPES
por: De Cola, Antonella, et al.
Publicado: (2023)

DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
por: Tsai, Jessica, et al.
Publicado: (2023)

DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA
por: Mudassar, Faiqa, et al.
Publicado: (2023)

DIPG-55. DIRECT BRAIN-TO-BRAIN WORKFLOW ENABLES THE PRECLINICAL MODELING OF PEDIATRIC GLIOMAS
por: Tum, Hong, et al.
Publicado: (2023)

DIPG-28. IDENTIFICATION AND TARGETING OF METABOLIC VULNERABILITIES IN COMBINATION WITH PDGFRA-INHIBITION IN DIFFUSE MIDLINE GLIOMA
por: Neyazi, Sina, et al.
Publicado: (2023)

DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2023)

DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023)

DIPG-06. PRECLINICAL EVALUATION OF A NOVEL ACVR1 INHIBITOR IN DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Kumar, Shiva Senthil, et al.
Publicado: (2023)

DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
por: Casillo, Stephanie, et al.
Publicado: (2023)

DIPG-41. EXPLORING BRAIN PENETRANT PEPTIDE-DRUG CONJUGATES IN DIFFUSE INTRINSIC PONTINE GLIOMA MODELS
por: Clark, Jasmine, et al.
Publicado: (2023)

DIPG-21. LINKING DETERMINATION OF CELL FATE IN THE DEVELOPING CENTRAL NERVOUS SYSTEM TO DIFFUSE MIDLINE GLIOMA
por: Furst, Liam, et al.
Publicado: (2023)

DIPG-11. DISSECTING THE DIFFUSE MIDLINE GLIOMA TUMOR MICROENVIRONMENT COMMUNICATIONS USING MULTI-OMICS APPROACHES
por: Collot, Raphael, et al.
Publicado: (2023)

DIPG-56. PEDIATRIC GLIOMAS EXHIBIT A UNIQUE LIPID METABOLIC PHENOTYPE DISTINCT FROM ADULT GBMS
por: Salinas, Jennifer, et al.
Publicado: (2023)

DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
por: Shen, Han, et al.
Publicado: (2023)

DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-24. BRD4 INHIBITION AS A RADIOSENSITIZER THROUGH BLOCKING DNA REPAIR FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
por: Watanabe, Jun, et al.
Publicado: (2023)

DIPG-51. ABDOMINAL METASTASES OF DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED WITH A VENTRICULOPERITONEAL SHUNT
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-31. HIF-1A AND HIF-2A COMBINATORIAL TARGETING OR HOW TO REVERSE THEIR BALANCED ONCOGENIC IMPACT
por: Fuchs, Quentin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_an9s23l7f2l9p7109gtm1rsa1t